MethylGene Inc. (TSX:MYG) and Pharmion Corporation (Nasdaq: PHRM) today announced preliminary data from two ongoing Phase II studies with MGCD0103, the Companies' novel, isotype- selective histone deacetylase (HDAC) inhibitor, as a single-agent in the treatment of Hodgkin lymphoma (HL) and non- Hodgkin lymphoma (NHL). Data from these studies were presented today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH).
MethylGene and Pharmion report favorable results for Phase 2 single-agent studies in relapsed or refractory lymphomas
MethylGene and Pharmion report preliminary clinical data at the 2007 AACR-NCI-EORTC International Conference
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today reported preliminary clinical data from the Companies' MGCD0103 Phase I/II combination trial with Gemzar® (Trial 006). The data were presented in a poster session at the 2007 AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24th, 2007.
Methylgene and Pharmion announce collaboration to develop sirtuin inhibitors as anti-cancer agents
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.
